Dylan Koenig, PA
Physician Assistant · Munising, MINPI 1780156232
Payments from drug & device makers
Across 197 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$299
- GSK$220
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$196
- Teva Pharmaceuticals USA, Inc.$183
- AstraZeneca$134
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,41099%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,379 |
| Pfizer | 26 | $299 |
| GSK | 13 | $220 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $196 |
| Teva Pharmaceuticals USA, Inc. | 8 | $183 |
| AstraZeneca | 10 | $134 |
| Amgen | 7 | $129 |
| Bayer | 7 | $119 |
| Merck | 5 | $102 |
| Boehringer Ingelheim | 5 | $100 |
| Vertex | 1 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $72 |
| Novo Nordisk | 4 | $68 |
| Averitas Pharma Inc. | 1 | $66 |
| Exact Sciences | 2 | $47 |
| Lilly USA, LLC | 3 | $44 |
| Eisai Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $35 |
| Novartis | 2 | $32 |
| Dexcom, Inc. | 1 | $18 |
| Medline Industries LP | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
How this compares
$3,458 in reported general payments places this provider in the 90th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 22 | $109,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $54,566 |
| EliquisApixaban | 76 | $50,726 |
| FarxigaDapagliflozin Propanediol | 49 | $27,305 |
| OzempicSemaglutide | 26 | $24,732 |
| VraylarCariprazine Hcl | 17 | $23,460 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $22,883 |
| XareltoRivaroxaban | 37 | $20,573 |
| JanuviaSitagliptin Phosphate | 22 | $17,277 |
| EntrestoSacubitril/Valsartan | 23 | $16,432 |
| JardianceEmpagliflozin | 28 | $16,380 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,442 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,092 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,348 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $4,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $129 | $109,50322 claims |
| GSKTrelegy Ellipta | $220 | $54,56669 claims |
| PfizerEliquis | $299 | $50,72676 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $134 | $50,18984 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Stiolto Respimat | $100 | $37,26265 claims |
| Novo NordiskOzempic | $68 | $24,73226 claims |
| AbbVieVraylar | $1,379 | $23,46017 claims |
| Johnson & JohnsonXarelto | $17 | $20,57337 claims |
| MerckJanuvia | $102 | $17,27722 claims |
| NovartisEntresto | $32 | $16,43223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Munising
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.